Insulet Corp. Aktie
282,80 €
Deine Einschätzung
Insulet Corp. Aktie
Was spricht für und gegen Insulet Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Insulet Corp. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Insulet Corp. | 0,96 % | 4,20 % | 5,26 % | 25,72 % | 11,28 % | -10,61 % | 29,74 % |
| Bio-Rad Labs Inc. A | 1,22 % | -1,02 % | 2,65 % | -21,99 % | -13,72 % | -28,65 % | -50,28 % |
| Neogen Corp. | -4,59 % | 0,00 % | 7,88 % | -64,38 % | -56,67 % | - | - |
| Haemonetics Corp. | 30,09 % | - | - | - | - | - | - |
Kommentare
News
Insulet (PODD) Q2 Revenue Jumps 33%
Insulet (NASDAQ:PODD), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet Corporation’s (NASDAQ: PODD) recent outperformance has caught investors' attention and has earned it a designation as a top performer on the




